Chinese medical journal
-
Chinese medical journal · Feb 2023
Current status and future perspectives of bispecific antibodies in the treatment of lung cancer.
Monoclonal antibodies have been successfully incorporated into the current therapeutical landscape of lung cancer in the last decades. Recently, with technological advances, bispecific antibodies (bsAbs) have also shown robust efficacy in the treatment of malignant cancers, including lung cancer. ⋯ Here, we outline the mechanisms of action of bsAbs, related clinical data, ongoing clinical trials, and potent novel compounds of various types of bsAbs in clinical studies, especially in lung cancer. We also propose future directions for the clinical development of bsAbs, which might bring a new era of treatment for patients with lung cancer.
-
Chinese medical journal · Feb 2023
Global burden prediction of gastric cancer during demographic transition from 2020 to 2040.
Despite the decline in the incidence and mortality rates of gastric cancer (GC), the impact of demographic transition on the global burden of GC remains unclear. The current study aimed to estimate the global disease burden through 2040 by age, sex, and region. ⋯ Ageing and population growth will offset the decline in the incidence and mortality rate of GC, resulting in a substantial increase in the number of new cases and deaths. The age structure will continue to change, especially in high HDI regions, requiring more targeted prevention strategies in the future.
-
Chinese medical journal · Feb 2023
Downstream of kinase 3 promotes proliferation and inhibits apoptosis of prostate cancer via the NF-κB signaling pathway.
DOK3 (Downstream of kinase 3) is involved primarily with immune cell infiltration. Recent research reported the role of DOK3 in tumor progression, with opposite effects in lung cancer and gliomas; however, its role in prostate cancer (PCa) remains elusive. This study aimed to explore the role of DOK3 in PCa and to determine the mechanisms involved. ⋯ Our findings suggest that overexpression of DOK3 promotes PCa progression by activating the NF-κB signaling pathway.